Validation.
Preclinical product assessment.
Scope.
We evaluate your existing product in preclinical in vivo models. Use of the VivoXpand stamp is subject to review; it does not certify human efficacy or safety.
Evidence and deliverables.
Research questions, formulation identity, models, controls, measurements and reporting should be defined for the specific project. No product-specific efficacy or safety conclusion follows from the service name.
The availability and scope of reports, raw data and publications need confirmation. Human studies are distinct from preclinical studies; no completed human study is asserted here.
Limits and regulatory review.
Ingredient status, product labelling and permitted claims require review for the intended market. The VivoXpand stamp is not a clinical certification or regulatory approval.
Discuss project-specific feasibility, deliverables, intellectual property and commercial terms with VivoXpand.
Discuss a project.
Questions and answers.
What does validation involve?
VivoXpand presents validation as one of its partnership routes alongside the other services described here. The scope depends on the product, research question and intended market. An enquiry is not a guarantee of technical success, regulatory acceptance or a health benefit. The relevant evidence, responsibilities and deliverables should be reviewed before a project is agreed.
Do you manufacture?
VivoXpand states that it formulates the product in its final format and manages its manufacturing. This describes coordination of product development, not a claim that every product has the same production arrangements. For a specific partnership, the manufacturer, quality documentation, final specification and responsibilities need to be agreed and verified before launch.
Which markets do you cover?
The existing partnership material identifies the EU and Switzerland as current markets and describes expansion to the US in 2027 as a plan. A plan is not present authorization. Whether a specific formulation, ingredient, label or claim is accepted must be checked against the rules of the intended market before any commercial commitment.
Is exclusivity possible?
The existing partnership material says exclusivity may be agreed by territory or channel on a case-by-case basis. That does not mean every formulation or programme is available exclusively. The actual scope, duration, rights and conditions require agreement with VivoXpand. Public programme stages alone do not establish the terms of a licence or distribution arrangement.
Can you create the whole product?
VivoXpand describes a co-development process covering science, formulation, manufacturing coordination, branding, labelling and regulatory steps. The specific work and responsibilities depend on the agreed project. This is a service scope, not a promise that every candidate will succeed or receive approval. Evidence needs, feasibility and market-specific requirements should be reviewed before development proceeds.
Does the VivoXpand stamp certify human efficacy?
No. The VivoXpand stamp is a research and development mark, not a clinical certification or authorization of a health claim. Preclinical assessment describes findings under particular model conditions. The use of the stamp and supporting evidence must be reviewed for the specific product, and should not imply established efficacy or safety in humans.